Morimasa Takayama
Overview
Explore the profile of Morimasa Takayama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
230
Citations
1309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kubo T, Sugiura K, Tokita Y, Takano H, Takamisawa I, Takayama M, et al.
Heart
. 2025 Mar;
PMID: 40037766
Background: The Japanese Hypertrophic Cardiomyopathy Registry Study was designed to provide comprehensive, real-world insights into the clinical characteristics and management of hypertrophic cardiomyopathy (HCM) in Japan. Methods: This multicentre, prospective...
2.
Matsushita K, Harada K, Jimba T, Kohno T, Nakano H, Kitano D, et al.
Minerva Cardiol Angiol
. 2025 Feb;
PMID: 40012479
Background: The relationship between Body Mass Index (BMI) and acute heart failure (HF) remains ill-defined. This study aimed to compare the influence of BMI on in-hospital mortality between patients with...
3.
Matsuda J, Takano H, Imori Y, Ishihara K, Sangen H, Kubota Y, et al.
Heart Vessels
. 2025 Feb;
PMID: 39904772
We appreciate the comments from Arshad et al. regarding our study on long-term outcomes of alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) in Japan. Addressing concerns about sex-related...
4.
Shiraishi Y, Niimi N, Kohsaka S, Harada K, Kohno T, Takei M, et al.
Circ Cardiovasc Qual Outcomes
. 2025 Jan;
e011270.
PMID: 39866101
Background: The absence of practice standards in vasoactive agent usage for acute decompensated heart failure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. This study aimed...
5.
Matsuda J, Tokita Y, Hoshika L, Koyama K, Ishihara K, Kobayashi S, et al.
J Cardiol
. 2025 Jan;
PMID: 39848572
Background: Alcohol septal ablation (ASA) is used to treat drug-refractory hypertrophic obstructive cardiomyopathy (HOCM). Intraprocedural echocardiography is essential for identifying the septal area perfused by each septal branch; however, its...
6.
Abe R, Kitamura M, Takayama M
Eur Heart J
. 2025 Jan;
46(11):1079.
PMID: 39791528
No abstract available.
7.
Watanabe Y, Yoshikawa T, Arao K, Isogai T, Yamaguchi T, Egashira T, et al.
Am J Cardiol
. 2024 Nov;
237():29-34.
PMID: 39581523
Diabetes is a major risk factor for cardiovascular diseases. However, some reports have shown that diabetes has a low prevalence and is associated with favorable outcomes in takotsubo syndrome (TTS)....
8.
Matsuda J, Takano H, Imori Y, Ishihara K, Sangen H, Kubota Y, et al.
Heart Vessels
. 2024 Nov;
PMID: 39580779
Hypertrophic cardiomyopathy is characterized by significant left ventricular wall thickening, often leading to obstructive symptoms. Alcohol septal ablation (ASA) has emerged as an effective treatment for patients with hypertrophic obstructive...
9.
Kitaoka H, Ieda M, Ebato M, Kozuma K, Takayama M, Tanno K, et al.
Circ J
. 2024 Nov;
89(1):130-138.
PMID: 39505542
Background: Mavacamten, a cardiac myosin inhibitor, significantly improved symptoms and cardiac function vs. placebo in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in EXPLORER-HCM. However, the efficacy and safety profiles...
10.
Fukutomi M, Onishi T, Ando T, Higuchi R, Hagiya K, Saji M, et al.
Catheter Cardiovasc Interv
. 2024 Oct;
104(7):1469-1476.
PMID: 39402889
Background: A history of hospitalization for heart failure (HHF) before transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement is associated with the prognosis of patients with severe aortic...